Modigraf
What Modigraf is used for
Prophylaxis of transplant rejection in adult and paediatric, kidney, liver or heart allograft recipients. Treatment of allograft rejection resistant to treatment with other immunosuppressive medicinal products in adult and paediatric patients.
Approved use, as published by the European Medicines Agency.
Key facts
- Brand
- Modigraf
- Active substance
- tacrolimus
- Disease area
- Graft Rejection
- Medicine group
- Immunosuppressants
- ATC code
- L04AD02
- Marketing authorisation holder
- Astellas Pharma Europe B.V.
- Authorised in the EU since
- 2009
Official information
In India
- Tacrolimus: 326 brands in India
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Modigraf used for?
Prophylaxis of transplant rejection in adult and paediatric, kidney, liver or heart allograft recipients. Treatment of allograft rejection resistant to treatment with other immunosuppressive medicinal products in adult and paediatric patients.
What is the active substance in Modigraf?
Modigraf contains tacrolimus.
Who makes Modigraf?
The EU marketing authorisation holder is Astellas Pharma Europe B.V..
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU